Innovent Biopharmaceutical Transformation
Further Strengthening Commercial Portfolio With High
Potential Assets and Proven Commercial Capabilities
Fully-fledged Commercial Ecosystem +
Validated Track Record
More Products into visibility:
CD47/LAG3/TIGIT / VEGF Clusters
and more from 80 pre-clinical projects...
PCSK9
GLP1-GCGR
IL-23
KRAS G12C
+Rich and De-risked Portfolio
=
~RMB 20bn
Sales in 5 years
For over 15 approved
and late stage assets
Annual Product Revenue (RMB)
YoY growth (%)
BCMA CAR-T
CTLA-4
ROS1/NTRK
PI3K8*
4.0 bn
CYRAMZAⓇ
+69.0%
RETSEVMO®Ⓡ
Olverembatinib
2.4 bn
PemazyreⓇ
+133.0%
SULINNOⓇ
SULINNOⓇ
HALPRYZAⓇ
HALPRYZAⓇ
1.0 bn
BYVASDAⓇ
BYVASDAⓇ
TYVYTⓇ
TYVYTⓇ
TYVYTⓇ
2019
2020
2021
2022-est.2023
2024-2026
*Note: We plan to have communication with China NMPA regarding the potential submission of parsaclisib (PI3K8 inhibitor). Incyte has withdrawn the application of
parsaclisib in FL, MZL and MCL in the U.S. as a business decision and is not related to any changes in either the efficacy or safety of parsaclisib.
Innovent
Confidential
Copyright©2022 Innovent
Plus
Upside Potential
From early stage global
potential assets, and
continuous BD collaboration
16View entire presentation